Screener
Ligand Pharmaceuticals LGND Other Non-Current Liabilities
Other Non-Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesNoncurrent.
The source filing: Ligand Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000886163-26-000044
FAQ
- What is Ligand Pharmaceuticals's other non-current liabilities?
- Ligand Pharmaceuticals (LGND) reported other non-current liabilities of $17.22M in Q2 2026.
- How has Ligand Pharmaceuticals's other non-current liabilities changed year-over-year?
- Ligand Pharmaceuticals's other non-current liabilities increased by 19.8% year-over-year, from $14.37M to $17.22M.
- What is the long-term trend for Ligand Pharmaceuticals's other non-current liabilities?
- Over 5 years (2020 to 2025), Ligand Pharmaceuticals's other non-current liabilities has grown at a -11.6% compound annual growth rate (CAGR), from $30.87M to $16.63M.
- What does other non-current liabilities mean?
- Miscellaneous long-term obligations not classified in specific categories — pension liabilities, environmental remediation, and other long-term accruals.
Ask your AI about Ligand Pharmaceuticals's other non-current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude